No cell therapy for osteoporosis has received FDA approval. Trials remain investigational. Some European national medicines agencies have not formally approved any such product either; most clinical applications occur in private centres outside strict regulatory frameworks.
Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material. Osteoporosis occurs when remodelling becomes imbalanced, with too much removal and insufficient replacement, leaving a porous, fragile architecture vulnerable to fracture. Placental mesenchymal stem cells have attracted research interest because they can differentiate into osteoblasts, potentially helping restore bone-forming capacity. The mechanism appears to involve both direct cellular replacement of bone-building cells and the release of signalling molecules (cytokines) that shift the remodelling ratio back toward deposition. Early-stage trials are exploring whether cell therapy can slow or partially reverse the density loss that typically accelerates after oestrogen withdrawal in post-menopausal women, though robust efficacy data remain limited.
Sunt un candidat? → · Osteoporosis & Bone Health: full overview → · Cost Osteoporoza și Sănătatea Oaselor → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită